SEARCH

SEARCH BY CITATION

References

  • 1
    Prentice A. Diet, nutrition and the prevention of osteoporosis. Public Health Nutr. 2004; 7:22743.
  • 2
    Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd. The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008. Osteoporos Int. 2012; 23:81120.
  • 3
    Lin YC, Pan WH. Bone mineral density in adults in Taiwan: results of the Nutrition and Health Survey in Taiwan 2005–2008 (NAHSIT 2005–2008). Asia Pac J Clin Nutr. 2011; 20:28391.
  • 4
    Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002; 359:192936.
  • 5
    Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996; 11:15318.
  • 6
    McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA, Kiel DP. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004; 350:20429.
  • 7
    van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, Breteler MM, Lips P, Pols HA, Uitterlinden AG. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004; 350:203341.
  • 8
    Leboff MS, Narweker R, LaCroix A, Wu L, Jackson R, Lee J, Bauer DC, Cauley J, Kooperberg C, Lewis C, Thomas AM, Cummings S. Homocysteine levels and risk of hip fracture in postmenopausal women. J Clin Endocrinol Metab. 2009; 94:120713.
  • 9
    Gjesdal CG, Vollset SE, Ueland PM, Refsum H, Drevon CA, Gjessing HK, Tell GS. Plasma total homocysteine level and bone mineral density: the Hordaland Homocysteine Study. Arch Intern Med. 2006; 166:8894.
  • 10
    Enneman AW, van der Velde N, de Jonge R, Heil SG, Stolk L, Hofman A, Rivadeneira F, Zillikens MC, Uitterlinden AG, van Meurs JB. The association between plasma homocysteine levels, methylation capacity and incident osteoporotic fractures. Bone. 2012 Jun; 50(6):14015.
  • 11
    Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J Bone Miner Res. 2003; 18:178994.
  • 12
    Keun HC, Ebbels TM, Antti H, Bollard ME, Beckonert O, Schlotterbeck G, Senn H, Niederhauser U, Holmes E, Lindon JC, Nicholson JK. Analytical reproducibility in 1H NMR-based metabonomic urinalysis. Chem Res Toxicol. 2002; 15:13806.
  • 13
    Dumas ME, Maibaum EC, Teague C, Ueshima H, Zhou B, Lindon JC, Nicholson JK, Stamler J, Elliott P, Chan Q, Holmes E. Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal Chem. 2006; 78:2199208.
  • 14
    Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, Nicholson JK. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc. 2007; 2:2692703.
  • 15
    Long WF, Li L, Chen HQ, Tang Y, He XL, Jing RZ. 1H-NMR-based metabonomics analysis of plasma from osteoporotic rats induced by ovariectomy. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009; 40:8437.
  • 16
    Xue L, Wang Y, Liu L, Zhao L, Han T, Zhang Q, Qin L. A 1HNMR-Based metabonomics study of postmenopausal osteoporosis and intervention effects of Er-Xian decoction in ovariectomized rats. Int J Mol Sci. 2011; 12:763551.
  • 17
    Zhu X, Liu X, He P, Cao B, Lv Y, Zhang W, Ni X. Metabolomics in serum of ovariectomised rats and those exposed to 17beta-oestradiol and genistein. Gynecol Endocrinol. 2010; 26:7607.
  • 18
    Ma B, Zhang Q, Wang GJ, JY A, Wu D, Liu Y, Cao B, Liu LS, Hu YY, Wang YL, Zheng YY. GC-TOF/MS-based metabolomic profiling of estrogen deficiency-induced obesity in ovariectomized rats. Acta Pharmacol Sin. 2011; 32:2708.
  • 19
    Griffith JF, Yeung DK, Antonio GE, Lee FK, Hong AW, Wong SY, Lau EM, Leung PC. Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy. Radiology. 2005; 236:94551.
  • 20
    Nicholson JK, Lindon JC, Holmes E.Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999; 29:11819.
  • 21
    Fiehn O. Metabolomics—the link between genotypes and phenotypes. Plant Mol Biol. 2002; 48:15571.
  • 22
    Lerner UH. Bone remodeling in post-menopausal osteoporosis. J Dent Res. 2006; 85:58495.
  • 23
    Bidoli E, Schinella D, Franceschi S. Physical activity and bone mineral density in Italian middle-aged women. Eur J Epidemiol. 1998; 14:1537.
  • 24
    Nock NL, Patrick-Melin A, Cook M, Thompson C, Kirwan JP, Li L. Higher bone mineral density is associated with a decreased risk of colorectal adenomas. Int J Cancer. 2011; 129:95664.
  • 25
    Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem. 1995; 67:793811.
  • 26
    Nicholson G, Rantalainen M, Maher AD, Li JV, Malmodin D, Ahmadi KR, Faber JH, Hallgrimsdottir IB, Barrett A, Toft H, Krestyaninova M, Viksna J, Neogi SG, Dumas ME, Sarkans U, The Molpage C, Silverman BW, Donnelly P, Nicholson JK, Allen M, Zondervan KT, Lindon JC, Spector TD, McCarthy MI, Holmes E, Baunsgaard D, Holmes CC. Human metabolic profiles are stably controlled by genetic and environmental variation. Mol Syst Biol. 2011; 7:525.
  • 27
    Yu Z, Kastenmuller G, He Y, Belcredi P, Moller G, Prehn C, Mendes J, Wahl S, Roemisch-Margl W, Ceglarek U, Polonikov A, Dahmen N, Prokisch H, Xie L, Li Y, Wichmann HE, Peters A, Kronenberg F, Suhre K, Adamski J, Illig T, Wang-Sattler R. Differences between human plasma and serum metabolite profiles. PLoS One. 2011; 6:e21230.
  • 28
    Viant MR. Improved methods for the acquisition and interpretation of NMR metabolomic data. Biochem Biophys Res Commun. 2003; 310:943948.
  • 29
    Barton RH, Waterman D, Bonner FW, Holmes E, Clarke R, Nicholson JK, Lindon JC. The influence of EDTA and citrate anticoagulant addition to human plasma on information recovery from NMR-based metabolic profiling studies. Mol Biosyst. 2010; 6:21524.
  • 30
    Purohit PV, Rocke DM, Viant MR, Woodruff DL. Discrimination models using variance-stabilizing transformation of metabolomic NMR data. OMICS. 2004; 8:11830.
  • 31
    Eriksson L, Johansson E, Kettaneh-Wold N, Wold S. Introduction to multi- and megavariate data analysis using projection methods (PCA & PLS) scaling. Umetrics Academy; 1999.
  • 32
    van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics. 2006; 7:142.
  • 33
    Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS. MetaboAnalyst 2.0—a comprehensive server for metabolomic data analysis. Nucleic Acids Res. 2012; 40:W127W33.
  • 34
    Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995; 57:289300.
  • 35
    Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010; 31:266300.
  • 36
    Hodgkinson A, Jones MM, Marshall RW, Skerrow SM. Increase in plasma lactate at the menopause and its relation to the “anion gap”. Maturitas. 1984; 5:1716.
  • 37
    Li Z, McNamara JR, Fruchart JC, Luc G, Bard JM, Ordovas JM, Wilson PW, Schaefer EJ. Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. J Lipid Res. 1996; 37:188696.
  • 38
    Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, Holsboer F. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol. 1997; 51:53541.
  • 39
    Singer CA, Figueroa-Masot XA, Batchelor RH, Dorsa DM. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci. 1999; 19:245563.
  • 40
    Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003; 111:122130.
  • 41
    Cohen SA. Amino acid analysis using precolumn derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate. Methods Mol Biol. 2000; 159:3947.
  • 42
    Sengupta S, Park SH, Patel A, Carn J, Lee K, Kaplan DL. Hypoxia and amino acid supplementation synergistically promote the osteogenesis of human mesenchymal stem cells on silk protein scaffolds. Tissue Eng Part A. 2010; 16:362334.
  • 43
    Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol. 1983; 55:62834.
  • 44
    Owen OE, Trapp VE, Skutches CL, Mozzoli MA, Hoeldtke RD, Boden G, Reichard GA Jr. Acetone metabolism during diabetic ketoacidosis. Diabetes. 1982; 31:2428.
  • 45
    Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007; 18:42744.
  • 46
    Shan PF, Wu XP, Zhang H, Cao XZ, Gu W, Deng XG, Gu C, Liao EY. Bone mineral density and its relationship with body mass index in postmenopausal women with type 2 diabetes mellitus in mainland China. J Bone Miner Metab. 2009; 27:1907.
  • 47
    Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, Yu Q, Zillikens MC, Gao X, Rivadeneira F. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012; 27:31932.
  • 48
    Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin. 2009; 25:105772.
  • 49
    Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res. 1993; 8:56773.
  • 50
    Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med. 1995; 1:13114.
  • 51
    Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999; 140:16308.
  • 52
    Martin A, de Vittoris R, David V, Moraes R, Begeot M, Lafage-Proust MH, Alexandre C, Vico L, Thomas T. Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology. 2005; 146:36529.
  • 53
    Adami S, Braga V, Zamboni M, Gatti D, Rossini M, Bakri J, Battaglia E. Relationship between lipids and bone mass in 2 cohorts of healthy women and men. Calcif Tissue Int. 2004; 74:13642.
  • 54
    Brownbill RA, Ilich JZ. Lipid profile and bone paradox: higher serum lipids are associated with higher bone mineral density in postmenopausal women. J Womens Health (Larchmt). 2006; 15:26170.
  • 55
    Parhami F, Jackson SM, Tintut Y, Le V, Balucan JP, Territo M, Demer LL. Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J Bone Miner Res. 1999; 14:206778.
  • 56
    Serre CM, Farlay D, Delmas PD, Chenu C. Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone. 1999; 25:6239.
  • 57
    Skerry TM, Genever PG. Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci. 2001; 22:17481.
  • 58
    Chenu C, Serre CM, Raynal C, Burt-Pichat B, Delmas PD. Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone. 1998; 22:2959.
  • 59
    Gibney MJ, Walsh M, Brennan L, Roche HM, German B, van Ommen B. Metabolomics in human nutrition: opportunities and challenges. Am J Clin Nutr. 2005; 82:497503.
  • 60
    Yamaguchi T, Sugimoto T, Yano S, Yamauchi M, Sowa H, Chen Q, Chihara K. Plasma lipids and osteoporosis in postmenopausal women. Endocr J. 2002; 49:2117.
  • 61
    Orozco P., Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women. Eur J Epidemiol. 2004; 19:110512.
  • 62
    Cui LH, Shin MH, Chung EK, Lee YH, Kweon SS, Park KS, Choi JS., Association between bone mineral densities and serum lipid profiles of pre- and post-menopausal rural women in South Korea. Osteoporos Int. 2005; 16:197581.
  • 63
    Rapuri PB, Kinyamu HK, Gallagher JC, Haynatzka V. Seasonal changes in calciotropic hormones, bone markers, and bone mineral density in elderly women. J Clin Endocrinol Metab. 2002; 87:202432.
  • 64
    Frankenfeld CL, McTiernan A, Thomas WK, LaCroix K, McVarish L, Holt VL, Schwartz SM, Lampe JW. Postmenopausal bone mineral density in relation to soy isoflavone-metabolizing phenotypes. Maturitas. 2006; 53:31524.